Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Kymera Therapeutics, Inc.

Clinical trials sponsored by Kymera Therapeutics, Inc., explained in plain language.

Kymera Therapeutics, Inc. KYMR NASDAQ

A clinical-stage biotech developing targeted protein degradation drugs.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 3 Not yet finished but already full! 1 Completed 2

New pill shows promise for severe eczema sufferers

Disease control Ongoing

This study tests an oral medication called KT-621 for people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and affected body area compared to a placebo. The trial lasts 16 weeks with a follow-up open-labe…

Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control

Last updated Jul 02, 2026 00:00 UTC